Information Provided By: 
Fly News Breaks for January 30, 2017
RHHBY, PRTA
Jan 30, 2017 | 07:21 EDT
Oppenheimer analyst Jay Olson lowered his price target for Prothena (PRTA) to $70 from $77 ahead of Q4 earnings. Nonetheless, the analyst reiterates an Outperform rating on the shares, saying that his optimism is fueled by the broad pipeline that is based on an antibody discovery platform. Olson views the technology as partially validated by the company's partnership with Roche (RHHBY) for PRX002, which increases his confidence in the entire pipeline.
News For PRTA;RHHBY From the Last 2 Days
There are no results for your query PRTA;RHHBY
